查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1868247

血液传染病检查市场（按产品、技术、最终用户和应用划分）—2025-2032年全球预测

Bloodstream Infection Testing Market by Product, Technology, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血液传染传染病检查市场将成长至 22.2 亿美元，复合年增长率为 7.93%。

关键市场统计数据
基准年 2024 12亿美元
预计年份：2025年 13亿美元
预测年份 2032 22.2亿美元
复合年增长率 (%) 7.93%

本文全面概述了临床需求、实验室操作和诊断技术创新如何融合，从而改变血液传染病检查的实践。

血液感染疾病仍然是急诊和公共卫生领域的核心挑战，因此迫切需要诊断的准确性、速度和临床整合。近年来，诊断格局已从渐进式的实验室改进转向更广泛地关注快速、可操作的结果，这些结果能够直接指导抗菌药物管理和患者管理。随着临床医生和实验室负责人重新评估通讯协定，他们优先考虑那些能够加快标靶治疗速度，同时又能维持严格的品质和合规性标准的解决方案。

对推动血液感染诊断技术快速发展和新应用路径的技术、临床和监管转折点进行策略分析

血液感染检测领域正经历着变革性的转变，这主要得益于技术进步、临床路径的演变以及监管机构对更快、更有效诊断方法的推动。生物感测器设计、分子诊断和质谱分析的创新各自具有独特的优势。生物感测器简化了样本製备，并可实现快速检测，通常可在床边进行。分子诊断提高了灵敏度，并改善了病原体的鑑定。质谱分析可在既定的实验室工作流程中实现物种层级的可靠鑑定。综合运用这些技术，临床医师和实验室技术人员可选择的方案范围正在不断扩大。

评估2025年关税调整对血液传染传染病检查生态系的供应链韧性、筹资策略和营运计画的影响。

近期关税调整和贸易政策考量，特别是已宣布或正在考虑的2025年措施，对诊断耗材、仪器和组件的供应链产生了复杂的影响。关税增加了进口试剂、一次性抛弃式和专用仪器零件的到岸成本，进而波及采购週期和库存策略。为此，实验室和製造商正努力透过审查筹资策略、增加国内库存缓衝以及加快对替代供应商的资格认证，来降低对单一供应来源的依赖。

详细的細項分析突显了产品类别、平台技术、临床环境和应用需求之间的交集，这些交集会影响产品的采用和投资决策。

有效的市场区隔揭示了临床需求、技术能力和商业性机会的交集。透过对产品、技术、最终用户和应用等维度的详细分析，可以发现不同的采用模式。按产品类别划分，仪器吸引了寻求高通量和自动化的集中式实验室的投资；试剂和试剂盒是耗材管理和经常性收入模式的核心；软体则日益成为连接、分析和决策支援的基础。每个产品类型都需要不同的服务模式和检验标准，进而影响采购和生命週期管理决策。

区域比较评估：报销制度、监管重点与医疗服务模式对血流感染诊断采纳和部署的影响

区域趋势正在塑造需求模式和创新路径，美洲、欧洲、中东和非洲以及亚太地区的营运重点各不相同。在美洲，医疗系统优先考虑将新的诊断方法快速整合到临床通讯协定和以价值为导向的医疗服务倡议中，并评估其带来的显着疗效提升。这促使人们关注能够在诊疗现场提供可操作结果，同时又能维持实验室级品质以进行确认性检测的解决方案。

本文以产业视角，探讨领先的诊断设备製造商如何调整其产品组合、伙伴关係和检验策略，以推动产品应用并确保业务永续营运。

为了应对速度和精确度的双重挑战，主要企业正在重新定义其策略，同时投资于能够确保供应连续性和客户成功的服务模式。一些企业专注于垂直整合解决方案，将仪器与专有试剂和数据分析相结合，以增强效能管理和生命週期效益。另一些企业则优先考虑开放平台互通性和策略合作伙伴关係，这可以加速市场准入，并降低拥有各种现有设备的实验室采用新技术的门槛。

诊断开发人员和医疗保健领导者：关于加强血液感染检测供应链韧性、临床整合和实证医学的实用优先建议

为了维持临床服务的连续性和竞争优势，产业领导者必须采取务实的态度，平衡短期营运需求和长期技术投资。优先考虑可整合到现有工作流程中的模组化解决方案，有助于实验室减少营运中断并减轻验证负担。同时，有针对性地投资自动化和试剂效率提升，可以保护营运免受供应波动的影响。同样重要的是，制定多供应商筹资策略和完善的供应商选择程序，以避免对单一供应商的依赖，并在市场波动期间维持检测能力。

采用透明、以证据为导向的调查方法，整合同侪审查的研究、监管分析和相关人员访谈，确保获得可靠且可操作的洞见。

本执行摘要的研究整合了同行评审文献、监管指导文件、行业白皮书以及对临床实验室负责人、技术开发人员和采购专业人员的访谈，以确保观点多元化。临床检验研究和通讯协定审查的证据与营运报告和供应链分析进行交叉比对，以了解技术性能和实际应用挑战。受访者涵盖了各种医疗机构，包括急诊医院实验室、参考中心和照护现场，以确保研究结果能反映各种营运限制。

总之，该总结强调，技术创新、运作韧性和证据生成相结合是改善血液感染诊断结果的途径。

整体而言，血液传染病检查领域正朝着更灵活、整合和主导的模式发展，强调在维持严格的分析性能和品管标准的同时，快速获得具有临床指导意义的结果。生物感测器、培养系统、质谱和分子诊断等多种技术为应对不同的临床应用场景提供了互补途径，而最成功的应用将是那些能够将技术优势与目标医疗环境的实际操作相结合的应用。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 次世代定序平台整合到血液感染疾病诊断中，用于快速病原体鑑定
  • 新兴的抗菌药物抗药性分析检测指南败血症患者的个人化抗生素治疗
  • 引入照护现场分子诊断设备，以加速加护治疗病房中血流感染疾病的检测。
  • 开发一种多重免疫检测试剂盒，用于同时检测血液感染疾病中的细菌和真菌病原体
  • 推出用于血液感染管理远端监测和数据整合的数位健康平台
  • 微流体实验室晶片技术在自动化血液样本病原体富集和鑑定方面的进展
  • 监管奖励和报销改革，以促进医院采用新型血液感染检测诊断方法

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品分類的血液传染病检查市场

  • 装置
  • 试剂和试剂盒
  • 软体

9. 按技术分類的血液传染病检查市场

  • 生物感测器平台
    • 电化学生物感测器
    • 光学生物感测器
  • 基于文化的系统
    • 自动化培养系统
    • 手工培养方法
  • 质谱分析
    • MALDI-TOF质谱
  • 分子诊断
    • 次世代定序
    • PCR

第十章 按最终用户分類的血液传染病检查市场

  • 学术和研究机构
  • 医院检查室
  • 就地检验
  • 参考实验室

第十一章 依应用分類的血液传染病检查市场

  • 临床诊断
  • 研究
  • 监视和监测

第十二章 各地区血液传染病检查市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 血液传染病检查市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国血液传染病检查市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Becton Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Abbott Laboratories
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Luminex Corporation
    • QIAGEN NV
Product Code: MRR-4D00F1312BD4

The Bloodstream Infection Testing Market is projected to grow by USD 2.22 billion at a CAGR of 7.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.20 billion
Estimated Year [2025] USD 1.30 billion
Forecast Year [2032] USD 2.22 billion
CAGR (%) 7.93%

A comprehensive situational overview describing how clinical demand, laboratory operations, and diagnostic innovation are converging to transform bloodstream infection testing practices

Bloodstream infections remain a central challenge for acute care and public health, driving urgent demands on diagnostic accuracy, speed, and clinical integration. Over recent years, the diagnostic landscape has shifted from incremental laboratory improvements to a broader emphasis on rapid, actionable results that can directly inform antimicrobial stewardship and patient management. As clinicians and laboratory leaders reassess protocols, they prioritize solutions that shorten time to targeted therapy while maintaining rigorous quality and compliance standards.

The adoption of advanced diagnostics is reshaping workflows, with laboratories balancing the need for high-throughput capacity alongside the demand for near-patient testing in emergency and critical care environments. At the same time, research institutions and reference laboratories continue to push technical boundaries, validating new biomarkers and sequencing approaches that promise deeper etiological insights. These changes are occurring in a context of constrained budgets, heightened regulatory scrutiny, and supply chain sensitivities, which together create both obstacles and incentives for innovative providers.

Consequently, stakeholders must consider a diverse set of factors when evaluating diagnostic strategies: analytical performance, integration with electronic health records and laboratory information systems, operational impact on staffing and turnaround times, and the ability to support surveillance and public health reporting. The resulting priorities emphasize not only technological capability but also usability, interoperability, and proven clinical utility across varied care settings.

A strategic analysis of the technological, clinical, and regulatory inflection points driving rapid evolution and new adoption pathways in bloodstream infection diagnostics

The landscape of bloodstream infection testing is undergoing transformative shifts driven by converging technological advances, evolving clinical pathways, and regulatory momentum toward faster, more actionable diagnostics. Innovations in biosensor design, molecular methods, and mass spectrometry are each contributing distinct advantages: biosensors enable rapid, often bedside detection with reduced sample preparation; molecular diagnostics offer enhanced sensitivity and pathogen identification precision; and mass spectrometry provides robust species-level identification in established laboratory workflows. Taken together, these technologies are expanding the palette of options available to clinicians and laboratorians.

Alongside technical progress, there is a sustained clinical trend toward earlier targeted therapy, underpinned by growing antimicrobial stewardship programs that demand diagnostic evidence to justify narrower-spectrum treatments. This creates a feedback loop: as diagnostics deliver actionable results more quickly, clinical protocols adjust to leverage those results, which in turn drives demand for even faster and more integrated testing solutions. Regulatory frameworks and reimbursement policies are beginning to reflect this shift, increasingly rewarding demonstrable improvements in patient outcomes and system efficiencies rather than raw throughput alone.

Operationally, laboratories are rethinking workflows to incorporate modular testing strategies that balance central laboratory capacity with decentralized point-of-care options. Interoperability with laboratory information systems and electronic health records has become a critical enabler of rapid result distribution and decision support. At the same time, developers and providers are paying closer attention to usability, automation, and supply continuity to reduce the burden on constrained clinical teams. These combined forces are not only changing product roadmaps but also influencing procurement criteria, partnership models, and long-term clinical adoption pathways.

An evaluation of how 2025 tariff shifts have reshaped supply chain resilience, procurement strategies, and operational planning across the bloodstream infection testing ecosystem

Recent tariff adjustments and trade policy considerations, especially measures announced or contemplated in 2025, have created a complex overlay on supply chains for diagnostic consumables, instruments, and components. Tariffs can increase landed costs for imported reagents, single-use disposables, and specialized instrument parts, which then reverberate across procurement cycles and inventory strategies. Laboratories and manufacturers have responded by reassessing sourcing strategies, increasing onshore inventory buffers, and accelerating qualification of alternative suppliers to mitigate single-source dependencies.

These dynamics have practical implications for procurement timelines and capital allocation. Buyers may shift toward longer contracts with domestic or tariff-exempt suppliers, preferring predictable supply terms over marginal cost advantages. Meanwhile, manufacturers face pressure to optimize manufacturing footprints, balance production between domestic and international sites, and adjust pricing structures to preserve commercial viability without undermining customer relationships. In some cases, tariffs have incentivized localized assembly or component manufacturing to reduce exposure to cross-border levies and promote supply resilience.

Beyond direct cost implications, tariff-driven realignments affect innovation velocity and collaboration models. Companies may defer noncritical upgrades or slow international rollouts while reassessing cost models. Conversely, some organizations accelerate investments in automation and reagent efficiency to lower per-test variable costs and sidestep tariff escalations. For clinical laboratories, the cumulative impact has been a renewed focus on operational flexibility: multi-vendor procurement strategies, increased validation of platform interchangeability, and strategic stockpiling where feasible to avoid diagnostic interruptions. These adaptations aim to preserve clinical continuity while managing budgetary constraints and regulatory compliance amid an evolving trade environment.

A detailed segmentation-driven perspective revealing where product classes, platform technologies, care settings, and application needs intersect to influence adoption and investment decisions

Effective segmentation reveals where clinical need, technical capability, and commercial opportunity intersect, and a nuanced view across product, technology, end user, and application slices illuminates distinct adoption patterns. When analyzed by product, instruments attract investments from centralized laboratories seeking throughput and automation, reagents and kits are focal for consumables management and recurring revenue models, and software increasingly underpins connectivity, analytics, and decision support. Each product category demands different service models and validation criteria, influencing procurement and lifecycle management decisions.

Considering technology, biosensor platforms offer rapid, often near-patient detection and are evolving along electrochemical and optical modalities that favor different sample types and use cases. Culture based systems remain foundational for pathogen isolation and susceptibility testing, with automated culture systems streamlining workflow and manual culture methods retaining relevance in resource-constrained settings. Mass spectrometry, particularly MALDI ToF MS, has become a workhorse for species identification where laboratory throughput and accuracy are paramount. Molecular diagnostics, including next generation sequencing and PCR, deliver deep pathogen characterization and resistance profiling, supporting both clinical decision-making and surveillance objectives.

From an end-user perspective, academic and research institutes continue to advance method development and validation studies, hospital laboratories focus on integrating rapid diagnostics into care pathways to reduce length of stay and improve outcomes, point of care testing brings immediacy to emergency and critical care settings where time is critical, and reference laboratories concentrate on specialized testing, confirmation, and epidemiological support. Application-driven segmentation differentiates clinical diagnosis needs from research priorities and surveillance and monitoring obligations, each with distinct performance, throughput, and regulatory demands. Understanding these intersecting segments helps stakeholders prioritize investments that match technical strengths to user needs and application constraints.

A comparative regional assessment describing how reimbursement, regulatory priorities, and healthcare delivery models shape the adoption and deployment of bloodstream infection diagnostics

Regional dynamics shape both demand patterns and innovation pathways, with distinct operational priorities in the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems emphasize rapid integration of new diagnostics into clinical protocols and value-based care initiatives that reward demonstrable outcome improvements. This drives interest in solutions that can provide actionable results at the point of care while maintaining laboratory-level quality for confirmatory testing.

In Europe, Middle East & Africa, regulatory harmonization efforts and national public health priorities guide procurement and adoption, and there is marked interest in diagnostics that can support surveillance networks and antimicrobial resistance monitoring across diverse care environments. Meanwhile, Asia-Pacific exhibits strong demand for scalable, cost-efficient testing solutions that can meet both high-volume urban centers and resource-limited rural settings. Market participants across all regions are negotiating trade-offs between centralized high-throughput platforms and decentralized rapid tests to optimize clinical pathways and resource utilization.

Across geographies, interoperability with health IT infrastructure, supply chain robustness, and local manufacturing considerations influence deployment strategies. Regional reimbursement frameworks and public health policy also determine how quickly novel diagnostics move from validation to routine use, with some jurisdictions prioritizing immediate clinical impact and others focusing on longer-term surveillance capabilities. These regional nuances require tailored commercial approaches and regulatory planning to ensure successful technology adoption and sustained clinical integration.

An industry-focused examination of how leading diagnostics organizations are aligning product, partnership, and evidence strategies to accelerate uptake and secure operational resilience

Leading players are redefining their strategies to address the dual imperatives of speed and accuracy while also investing in service models that ensure supply continuity and customer success. Some firms are concentrating on vertically integrated solutions that pair instruments with proprietary reagents and data analytics, enabling a tighter control of performance and lifecycle revenue. Others prioritize open-platform interoperability and strategic partnerships that accelerate market access and lower barriers to adoption for laboratories with diverse existing equipment.

Collaboration between technology providers, clinical networks, and academic centers is becoming more common, as companies seek real-world evidence and validation studies that demonstrate clinical utility and support regulatory submissions. Investment in software and informatics capabilities is another notable trend: advanced laboratory information management integration, result interpretation algorithms, and antimicrobial stewardship decision support are increasingly valued additions to core diagnostic offerings. Companies are also exploring business models that reduce upfront capital burdens for customers, including reagent-as-a-service or outcome-linked agreements, to facilitate uptake in budget-constrained environments.

In parallel, many organizations are enhancing their global supply chain strategies to mitigate tariff exposure and logistical disruptions. This includes diversifying supplier bases, locating critical manufacturing closer to key markets, and strengthening distribution partnerships. Together, these strategic moves reflect a competitive environment where differentiation rests on a combination of technological performance, evidence generation, customer support, and operational reliability.

Practical, prioritized recommendations for diagnostic developers and healthcare leaders to strengthen supply resilience, clinical integration, and evidence generation for bloodstream infection testing

Industry leaders should adopt a pragmatic approach that balances near-term operational needs with long-term technological investments to preserve both clinical continuity and competitive advantage. Prioritizing modular solutions that can be integrated into existing workflows reduces disruption and lowers validation overhead for laboratories, while investing selectively in automation and reagent efficiency helps insulate operations from supply volatility. Equally important is building multi-vendor procurement strategies and robust supplier qualification programs to avoid single-source dependencies and to sustain testing capacity during market shifts.

Strategic partnerships with clinical networks and academic collaborators will accelerate real-world evidence generation, which in turn supports regulatory submissions and payer dialogues. Investing in software and interoperability pays dividends by improving result routing, analytics, and stewardship integration; these capabilities enhance clinical utility and create stickiness for customers. Finally, scenario-based planning for trade and tariff impacts - including localized manufacturing where feasible and flexible contracting models - will reduce operational risk and preserve access to critical consumables during periods of policy uncertainty.

A transparent and evidence-driven methodology integrating peer-reviewed research, regulatory analysis, and stakeholder interviews to ensure robust and actionable insights

The research underpinning this executive summary synthesized peer-reviewed literature, regulatory guidance documents, industry white papers, and interviews with clinical laboratory leaders, technology developers, and procurement specialists to ensure a rounded perspective. Evidence from clinical validation studies and protocol reviews was cross-checked against operational reports and supply chain analyses to understand both technical performance and real-world implementation challenges. Interview subjects were selected to represent a diversity of care settings, including acute hospital laboratories, reference centers, and point-of-care environments, ensuring that findings reflect varied operational constraints.

Where possible, technical claims and adoption trends were corroborated by independent publications and regulatory filings to avoid reliance on promotional materials. The methodology prioritized transparency in source selection and clearly documented assumptions related to technology capabilities, regulatory context, and logistical constraints. This approach provides readers with a defensible analytical foundation for decision-making while acknowledging areas where further primary research or longitudinal data would strengthen confidence in long-term trends.

A concluding synthesis highlighting the convergence of technological innovation, operational resilience, and evidence generation as the pathway to improved diagnostic outcomes in bloodstream infections

In aggregate, the field of bloodstream infection testing is moving toward a more agile, integrated, and evidence-driven model that privileges rapid, clinically actionable results while maintaining rigorous standards for analytical performance and quality control. Technological diversity-spanning biosensors, culture systems, mass spectrometry, and molecular diagnostics-offers complementary routes to address different clinical use cases, and the most successful implementations will be those that align technical strengths with the operational realities of the targeted care environment.

At the same time, external pressures such as tariff changes, supply chain fragility, and evolving reimbursement priorities underscore the need for flexible procurement strategies and resilient operational planning. Organizations that invest in interoperability, real-world evidence generation, and strategic supplier relationships will be better positioned to deliver consistent diagnostic value. Ultimately, the path to improved patient outcomes hinges on aligning product innovation with clinical workflows, regulatory requirements, and pragmatic commercial models that enable sustainable adoption across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of next-generation sequencing platforms for rapid pathogen identification in bloodstream infection diagnostics
  • 5.2. Emergence of antimicrobial resistance profiling assays to guide personalized antibiotic therapy in sepsis patients
  • 5.3. Adoption of point-of-care molecular diagnostic devices to accelerate bloodstream infection detection in critical care settings
  • 5.4. Development of multiplex immunoassay panels for simultaneous detection of bacterial and fungal pathogens in blood infections
  • 5.5. Implementation of digital health platforms for remote monitoring and data integration in bloodstream infection management
  • 5.6. Advancements in microfluidic lab-on-a-chip technologies for automated pathogen enrichment and identification from blood samples
  • 5.7. Regulatory incentives and reimbursement reforms driving adoption of novel diagnostics for bloodstream infection testing in hospitals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bloodstream Infection Testing Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software

9. Bloodstream Infection Testing Market, by Technology

  • 9.1. Biosensor Platforms
    • 9.1.1. Electrochemical Biosensors
    • 9.1.2. Optical Biosensors
  • 9.2. Culture Based Systems
    • 9.2.1. Automated Culture Systems
    • 9.2.2. Manual Culture Methods
  • 9.3. Mass Spectrometry
    • 9.3.1. MALDI ToF Ms
  • 9.4. Molecular Diagnostics
    • 9.4.1. Next Generation Sequencing
    • 9.4.2. PCR

10. Bloodstream Infection Testing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospital Laboratories
  • 10.3. Point Of Care Testing
  • 10.4. Reference Laboratories

11. Bloodstream Infection Testing Market, by Application

  • 11.1. Clinical Diagnosis
  • 11.2. Research
  • 11.3. Surveillance & Monitoring

12. Bloodstream Infection Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bloodstream Infection Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bloodstream Infection Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Becton Dickinson and Company
    • 15.3.2. bioMerieux SA
    • 15.3.3. F. Hoffmann-La Roche AG
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Siemens Healthineers AG
    • 15.3.6. Abbott Laboratories
    • 15.3.7. Danaher Corporation
    • 15.3.8. Bio-Rad Laboratories, Inc.
    • 15.3.9. Luminex Corporation
    • 15.3.10. QIAGEN N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOODSTREAM INFECTION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION,